Skip to main content

Table 1 Patient and tumour characteristics of ER-positive postmenopausal breast cancer patients as whole and according to BMI categories

From: Observational study on the prognostic value of testosterone and adiposity in postmenopausal estrogen receptor positive breast cancer patients

  Total cases
N = 460
BMI < 25
N = 195
BMI 25–30
N = 141
BMI ≥30
N = 78
p-valuea
Histology
 IDC 350 (76.9%) 135 (71.1%) 113 (80.1%) 65 (83.3%) 0.132
 IDC + ILC 42 (9.2%) 19 (10.0%) 12 (8.5%) 6 (7.7%)
 ILC 63 (13.8%) 36 (18.9%) 16 (11.3%) 7 (9.0%)
 Other 5 5 0 0
Tumour size
 pT1 306 (67.1%) 137 (71.7%) 92 (65.2%) 46 (59.0%) 0.167
 pT2 121 (26.5%) 41 (21.5%) 42 (29.8%) 24 (30.8%)
 pT3-pT4 29 (6.4%) 13 (6.8%) 7 (5.0%) 8 (10.3%)
 NA 4 4 0 0
Tumour grade
 G1 35 (7.7%) 18 (9.4%) 9 (6.4%) 4 (5.1%) 0.166
 G2 293 (64.4%) 129 (67.2%) 82 (58.6%) 51 (65.4%)
 G3 127 (27.9%) 45 (23.4%) 49 (35.0%) 23 (29.5%)
 NA 5 3 1 0
Nodal status
 Negative 288 (64.3%) 122 (64.2%) 83 (61.5%) 44 (57.1%) 0.689
 Positive (1–2) 88 (19.6%) 34 (17.9%) 31 (23.0%) 18 (23.4%)
 Positive (> 2) 72 (16.1%) 34 (17.9%) 21 (15.6%) 15 (19.5%)
 NA 12 5 6 1
Progesterone receptor status
 Negative 103 (22.4%) 52 (26.7%) 24 (17.0%) 11 (14.1%) 0.025
 Positive 357 (77.6%) 143 (73.3%) 117 (83.0%) 67 (85.9%)
Androgen receptor status
 Negative 37 (8.5%) 18 (9.9%) 15 (10.9%) 2 (2.7%) 0.099
 Positive < 60% 162 (37.1%) 70 (38.5%) 50 (36.5%) 22 (29.7%)
 Positive ≥60% 238 (54.5%) 94 (51.6%) 72 (52.6%) 50 (67.6%)
 NA 23 13 4 4
HER2 status
 Negative 176 (55.5%) 78 (56.5%) 51 (51.0%) 27 (56.2%) 0.520
 Positive 2+ 90 (28.4%) 42 (30.4%) 28 (28.0%) 15 (31.2%)
 Positive 3+ 51 (16.1%) 18 (13%) 21 (21.0%) 6 (12.5%)
 NA 143 57 41 30
Endocrine therapy
 No 30 (6.5%) 14 (7.2%) 6 (4.3%) 5 (6.4%) 0.543
 Yes 429 (93.5%) 181 (92.8%) 134 (95.7%) 73 (93.6%)
 NA 1 0 1 0
  1. aAll p-values were evaluated excluding NA category or Other category for Histology variable
  2. ER Estrogen Receptor, IDC Invasive Ductal Carcinoma, ILC Invasive Lobular Carcinoma, NA Not Available data